Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 10 versus PREMASOL 6 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 10 versus PREMASOL 6 IN PLASTIC CONTAINER.
AMINOSYN II 10% vs PREMASOL 6% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and nitrogen balance maintenance in patients unable to tolerate adequate oral/enteral intake.
Intravenous amino acid solution providing essential and non-essential amino acids for protein synthesis, nitrogen balance, and maintenance of lean body mass. Amino acids are actively transported into cells and incorporated into proteins; also serves as a caloric source.
Intravenous infusion: 500 mL to 1 L of 10% solution (50-100 g amino acids) per day, administered at a rate not exceeding 100 mL/h. Typical initial dose: 0.8-1.5 g/kg/day of amino acids, adjusted based on metabolic needs and tolerance.
Intravenous infusion: 1 to 1.5 g/kg/day (amino acids) as part of total parenteral nutrition; typically 500 mL to 1000 mL per day, infused over 12-24 hours.
None Documented
None Documented
Variable depending on metabolic state; for individual amino acids, half-lives range from 10 to 100 minutes. In renal impairment, accumulation can occur. No single terminal half-life for the mixture.
Amino acids have rapid plasma clearance; elimination half-life varies from minutes to hours depending on individual amino acid; clinically, infused amino acids are cleared within 2-4 hours after infusion cessation.
Primarily renal as amino acids and metabolites; >90% of infused amino acids are reabsorbed by proximal tubules, with less than 10% excreted unchanged in urine. Biliary/fecal excretion negligible.
Renal elimination of amino acids and metabolites; complete metabolism with nitrogen excretion as urea in urine; minimal biliary/fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution